Photo of Patrik Nasr

Patrik Nasr

Adjunct Associate Professor

M.D., Ph.D., Postdoc. My main interests in research are epidemiology and non-invasive diagnosis of chronic liver diseases, and especially non-alcoholic fatty liver disease (NAFLD).

Non-invasive diagnosis of fatty liver disease and sarcopenia

I received my medical degree from Linköping University in 2013 and I'm doing a residency in internal medicine and in gastroenterology and hepatology at Linköping University Hospital. I defended my thesis "Non-Alcoholic Fatty Liver Disease: Aspects on Diagnosis and Long-term Prognosis" in 2019 and I'm currently involved in several prospective studies focusing on chronic liver diseases (mainly NAFLD) and cirrhosis as part of The Study Group of Ectopic Fat Storage. Furthermore, I’m doing a postdoc at the Karolinska Institute, as part of the Hagström group.

Chronic liver diseases are highly prevalent globally. Non-alcoholic fatty liver disease, or NAFLD, is the most common chronic liver disease, affecting approximately 25% of the adult population worldwide. NAFLD is often seen as the hepatic manifestation of the metabolic syndrome, which includes overweight/obesity, type 2 diabetes mellitus, dyslipidemia, and hypertension. The prevalence of NAFLD is expected to rise in parallel with the ongoing epidemic of obesity and type 2 diabetes mellitus.

NAFLD entails an increased risk of liver-related events associated with cirrhosis, such as ascites, esophageal varices, hepatic encephalopathy, and hepatocellular carcinoma (HCC). Even though NAFLD progresses slowly (over decades), and only circa 5% develop cirrhosis, it is now the leading cause of HCC and the second leading etiology for liver transplantation.

The gold standard for diagnosing and staging chronic liver diseases is by histopathological evaluation, which requires a liver biopsy. However, recently, novel biomarkers such as magnetic resonance (MR) imaging, has shown promise in replacing liver biopsy for quantification and evaluation of hepatic fat accumulation and fibrosis, portal blood flow, body composition and sarcopenia.

Currently, the most validated non-invasive biomarkers are easily available blood-based scores, advanced MR exams and vibration controlled transient elastography (e.g., Fibroscan®). However, several new biomarkers are under investigation, with experimental blood- and gene-based analyses, radiological techniques, and cytokines being thoroughly evaluated. Moreover, body composition, sarcopenia, and structural heart changes have shown an intricate relationship associated with cardiovascular and liver-related outcome in individuals with chronic liver diseases.

The relationship between body composition, sarcopenia and chronic liver diseases is poorly understood. However, sarcopenia seems to be associated with a more dismal prognosis in patients with chronic liver diseases, and especially liver cirrhosis.

The main purpose of our projects is to untangle the relationship between chronic liver disease, body composition and sarcopenia, and its relevance for diagnosis, prognosis, and treatment. Furthermore, we aim to define clinically relevant risk phenotypes amongst individuals with chronic liver diseases, and especially non-alcoholic fatty liver disease.

About me


  • 2007-2013 Medical Degree, Linköping University, Sweden
  • 2013-2015 Internship, Linköping University Hospital (US), Sweden
  • 2015- Resident, Internal medicine, US, Sweden
  • 2015- Resident, Gastroenterology and Hepatology, US, Sweden
  • 2020- Postdoc, Karolinska Institutet, Stockholm, Sweden
  • 2020- Member of the Linköping Medical Association

Teaching assignments

  • 2013- Teaching assignments at the Medical Programme Linköping
  • 2021- Co-supervisor for PhD-students
  • 2015- Examiner at the Medical Programme in Linköping



Cover of publication 'image from publication'
Patrik Nasr, Mikael F. Forsgren, Simone Ignatova, Nils Dahlström, Gunnar Cedersund, Olof Dahlqvist Leinhard, Bengt Norén, Mattias Ekstedt, Peter Lundberg, Stergios Kechagias (2017)

Gastroenterology , Vol.153 , s.53-+ Continue to DOI

Cover of publication ''
Patrik Nasr, Simone Ignatova, Stergios Kechagias, Mattias Ekstedt (2018)

Hepatology communications , Vol.2 , s.199-210 Continue to DOI

Cover of publication ''
Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stal, Rolf Hultcrantz, Stergios Kechagias (2017)

Journal of Hepatology , Vol.67 , s.1265-1273 Continue to DOI


Ferenc E. Mozes, Jenny A. Lee, Yasaman Vali, Osama Alzoubi, Katharina Staufer, Michael Trauner, Rafael Paternostro, Rudolf E. Stauber, Adriaan G. Holleboom, Anne-Marieke van Dijk, Anne Linde Mak, Jerome Boursier, Marc de Saint Loup, Toshihide Shima, Elisabetta Bugianesi, Silvia Gaia, Angelo Armandi, Shalimar, Monica Lupsor-Platon, Vincent Wai-Sun Wong, Guanlin Li, Grace Lai-Hung Wong, Jeremy Cobbold, Thomas Karlas, Johannes Wiegand, Giada Sebastiani, Emmanuel Tsochatzis, Antonio Liguori, Masato Yoneda, Atsushi Nakajima, Hannes Hagstrom, Camilla Akbari, Masashi Hirooka, Wah-Kheong Chan, Sanjiv Mahadeva, Ruveena Rajaram, Ming-Hua Zheng, Jacob George, Mohammed Eslam, Salvatore Petta, Grazia Pennisi, Mauro Vigano, Sofia Ridolfo, Guruprasad Padur Aithal, Naaventhan Palaniyappan, Dae Ho Lee, Mattias Ekstedt, Patrik Nasr, Christophe Cassinotto, Victor de Ledinghen, Annalisa Berzigotti, Yuly P. Mendoza, Mazen Noureddin, Emily Truong, Celine Fournier-Poizat, Andreas Geier, Miljen Martic, Theresa Tuthill, Quentin M. Anstee, Stephen A. Harrison, Patrick M. Bossuyt, Michael Pavlides (2023) Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis The Lancet Gastroenterology & Hepatology, Vol. 8, p. 704-713 Continue to DOI
Jane Knochel, Linnea Bergenholm, Eman Ibrahim, Stergios Kechagias, Sara Hansson, Mathias Liljeblad, Patrik Nasr, Bjorn Carlsson, Mattias Ekstedt, Sebastian Ueckert (2023) A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts CPT: Pharmacometrics and Systems Pharmacology (PSP) Continue to DOI
Julia Blomdahl, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias (2023) Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD HEPATOLOGY COMMUNICATIONS, Vol. 7 Continue to DOI
Patrik Nasr, Erik von Seth, Raphaela Mayerhofer, Nelson Ndegwa, Jonas F. F. Ludvigsson, Hannes Hagstrom (2023) Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019 European Journal of Epidemiology Continue to DOI
Jennifer Linge, Patrik Nasr, Arun J. Sanyal, Olof Dahlqvist Leinhard, Mattias Ekstedt (2023) Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD JHEP REPORTS, Vol. 5, Article 100663 Continue to DOI


Research projects:

  • NFL
  • FLIS-2
  • UK Biobank
Microscopy image of liver. White areas represent accumulated fat.

Non-alcoholic fatty liver disease

Our research purposes are to further characterize the natural history of NAFLD, identify factors that influence the progression and to develop and validate diagnostic methods for NAFLD.

Photo of EPSONIP project meeting


EPSONIP explores the link between fatty liver, epicardial fat and cardiovascular disease in type 2 diabetes.

Research Networks


  • Mattias Ekstedt
  • Wile Balkhed
  • Julia Blomdahl
  • Byron Lykiardopoulo
  • Stergios Kechagias
  • Mikael Forsgren
  • Olof Dahlqvist Leinhardt
  • Jennifer Linge
  • Gunnar Cedersund
  • Valentin Kindesjö
  • Nils Dahlström
  • Bengt Norén
  • Wolf Bartholomä
  • Peter Lundberg
  • Johan Kihlberg
  • Carl Johan Carlhäll
  • Tino Ebbers
  • Carl Edin
  • Joakim Alfredsson
  • Torsten Olbers
  • Bijar Ghafour
  • Cecilia Jönsson
  • Christian Simonsson
  • Martin Henriksson
  • Lina Gruneau
  • Fredrik Iredahl
  • Martin Ulander
  • Martin Bergram
  • Karin Rådholm
  • Simone Ignatova